Health Affairs, 26, no. 3 (2007): 750-760 doi: 10.1377/hlthaff.26.3.750 © 2007 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Polinski, J. M. Articles by Fischer, M. A. Search for Related Content PubMed Articles by Polinski, J. M. Articles by Fischer, M. A. Related Collections Access To Care Consumer Issues Managed Care - Medicaid Medicaid Mental Health/Substance Abuse Pharmaceuticals

Case Studies

Medicaid’s Prior Authorization Program And Access To Atypical Antipsychotic Medications

State Medicaid programs use prior authorization (PA) to control drug spending by requiring that specific conditions be met before allowing reimbursement. The extent to which PA policies respond to new developments concerning medication safety is not known. In April 2005 the Food and Drug Administration (FDA) issued an advisory describing increased mortality among elderly people with dementia taking atypical antipsychotics. More than a year later, no state had changed its PA policy in response. We discuss the roles of Medicaid and other insurers in responding to emerging drug safety issues and their challenges in weighing drug risks and benefits.

                      What's this?

This article has been cited by other articles:

				J. J. Parks, A. Q. Radke, and R. Tandon Impact of the CATIE Findings on State Mental Health Policy Psychiatr Serv, May 1, 2008; 59(5): 534 - 536. [Abstract] [Full Text] [PDF]

				M. R. Law, D. Ross-Degnan, and S. B. Soumerai Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements Psychiatr Serv, May 1, 2008; 59(5): 540 - 546. [Abstract] [Full Text] [PDF]

				S. B. Soumerai, F. Zhang, D. Ross-Degnan, D. E. Ball, R. F. LeCates, M. R. Law, T. E. Hughes, D. Chapman, and A. S. Adams Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change Health Aff., May 1, 2008; 27(3): w185 - w195. [Abstract] [Full Text] [PDF]

				G. M. Anderson, D. Juurlink, and A. S. Detsky Newly Approved Does Not Always Mean New and Improved JAMA, April 2, 2008; 299(13): 1598 - 1600. [Full Text] [PDF]

eLetters: